Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQD5NA)

• Drug Name: TD-9855 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Phase 2	[1]
Orthostatic hypotension	BA21	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 46189893
  CAS Number: CAS 1227056-84-9
  TTD Drug ID: DMQD5NA

Molecule-Related Drug Atlas

Drug(s) Targeting Norepinephrine transporter (NET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[3]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[4]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[5]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[3]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[6]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[7]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[8]
Venlafaxine	DMR6QH0	Anxiety disorder	6B00-6B0Z	Approved	[7]
Trimipramine	DM1SC8M	Major depressive disorder	6A70.3	Approved	[9]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[10]

Drug(s) Targeting Serotonin transporter (SERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[3]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[4]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[11]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[12]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[6]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[7]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[11]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[11]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Modulator	[1]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Modulator	[1]

References

• [1] Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [4] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [5] Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
• [6] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [7] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [8] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [9] Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
• [10] Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [12] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [13] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.